Neil Bertelsen, member of Patient Focused Medicines Development (PFMD) and former chair of Health Technology International (HTAi), explores how to improve the barriers and limitations in the drug development process?
For too long, the established research community, in both academia and industry, have dictated the direction, shape and outcomes of medical research. Today, people living with conditions demand and expect a role in shaping the science that will deliver meaningful impacts to their future lives.